Quantitative Staging and Therapeutic Response in IDH-1 Mutated Glioblastomas
Quantitative Staging and Therapeutic Response in IDH-1 Mutated Glioblastomas
批准号:
9221508
负责人:
Brian J Soher
金额:
$35.92万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-03-01 至 2019-02-28
关键词:
Active SitesAnatomyAppointmentBrain NeoplasmsCancer EtiologyChildClinicClinicalClinical TrialsComputer softwareConsentDataDecision MakingDevelopmentDiagnosisExcisionFoodFutureGeneral HospitalsGlioblastomaGliomaGoalsGrowthImmunotherapeutic agentImmunotherapyIndustrializationInjection of therapeutic agentInterventionIsocitrate DehydrogenaseMagnetic ResonanceMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMalignant - descriptorMalignant neoplasm of brainMassachusettsMeasurementMeasuresMetabolicMethodsMonitorMutateMutationOperative Surgical ProceduresParentsPatientsPhasePhysiologic pulsePositioning AttributePrimary Brain NeoplasmsProtocols documentationPublic HealthRadiology SpecialtyRecruitment ActivityResearchResearch PersonnelSafetyScanningScheduleSignal TransductionSourceStagingStandardizationTherapeuticTherapeutic EffectTherapeutic InterventionTimeToxic effectTumor AntigensVaccinesVariantVisitWorkbasechildhood cancer mortalityclinical translationcompliance behaviordata acquisitiondosageimmunogenicitymedical appointmentneoplastic cellnovel vaccinesopen sourceoverexpressionphase I trialphase II trialsafety testingsimulationstandard of caretooltreatment responsetreatment trialtumortumor metabolismyoung adult
中文摘要
目标:我们将全面描述一套使用2-
羟基戊二酸(2HG)监测异柠檬酸脱氢酶1突变的免疫治疗干预
(IDH1+)胶质瘤。杜克大学将于2016年春季开始招聘,进行临床试验,以测试安全性和
IDH1+疫苗在II级胶质瘤患者中的免疫原性;这将是这项提议的父母试验。
背景:胶质母细胞瘤是儿童和年轻人中最恶性的原发脑瘤,具有
中位总生存期为15个月。低级别胶质瘤的患者通常进展为这种致命的肿瘤。
在10年内打字。目前对这些肿瘤的治疗是无能为力的,而且受到非特异性毒性的限制。在……里面
相比之下,免疫疗法承诺了一种精准的治疗方法。一种高度保守的肿瘤
杜克大学的研究人员发现了专门位于IDH1活性位点的特定突变。这种突变
在几乎所有的胶质瘤亚型中都有70%出现,并被用来开发IDH1特异性疫苗。一位直接的
IDH1突变的结果是肿瘤代谢物2HG的极端过度表达,这是可以测量的
非侵入性地使用磁共振波谱。野生的IDH1胶质瘤中的2HG浓度低于
MRS检测使2HG成为IDH1+突变胶质瘤的特异性标志物。方法:我们将创建一个
标准化的MRS方案,解释了疫苗接种期间肿瘤表现的初始变化
应用期间,肿瘤切除前。我们已经与一个财团合作进行MRS的临床翻译
方法在马萨诸塞州总医院(MGH),由奥维迪乌·安德罗内西博士领导。我们将创建一个
2HG测量的标准协议,使用1)MGH 2HG验证的兆次激光脉冲序列
西门子磁共振扫描仪;2)西门子用于纵向体素重新定位的自动体素对齐软件;
3)索尔博士的开源“VESPA”软件,用于光谱模拟和百万级激光数据的拟合。
我们将在多时间点工作流中演示该方法的可行性和可重复性,并测量
同日代谢物的变异系数,以便在第二阶段试验中使用。我们将测量2HG
在所有接受IDH1+疫苗的患者中。患者将在我们的研究西门子Trio扫描仪上进行扫描,地址为
在大约6-8周的时间里,他们在手术切除前接种疫苗。影响:我们的
长期假设是,针对2HG优化的MRS方案可以为临床医生提供强大的代谢
对治疗干预措施的效果提供直接和可能更早的衡量的措施
其他MR措施,如肿瘤增强和/或不增强。目前的提案提供了一个
与我们的父母I期免疫治疗试验合作的无与伦比的机会
优化一种用于量化肿瘤代谢的特征良好的工具,以用于后续的第二阶段试验。
我们将确定在这组患者中采取2HG措施的最佳实践,并演示
在患者耐受性和数据稳健性方面,将这一措施纳入我们的研究/临床工作流程。
英文摘要
Objective: We will fully characterize a set of best practices for using quantitative measures of 2-
hydroxyglutarate (2HG) to monitor an immunotherapeutic intervention in isocitrate dehydrogenase 1 mutated
(IDH1+) gliomas. Recruitment begins at Duke in Spring 2016 for a clinical trial to test safety and
immunogenicity of an IDH1+ vaccine in grade II gliomas patients; this will be the parent trial for this proposal.
Background: Glioblastoma, the most malignant primary brain tumor in children and young adults, has a
median overall survival of <15 months. Patients with lower grade gliomas typically progress to this lethal tumor
type within 10 years. Current therapy for these tumors is incapacitating and limited by non-specific toxicity. In
contrast, immunotherapy promises an exquisitely precise therapeutic approach. A highly conserved and tumor
specific mutation exclusively at the IDH1 active site was discovered by researchers at Duke. This mutation
occurs in >70% of almost all glioma subtypes and was used to develop an IDH1 specific vaccine. A direct
result of the IDH1 mutation is the extreme overexpression of the onco-metabolite 2HG which can be measured
non-invasively using MR spectroscopy. 2HG concentrations in ‘wild’ IDH1 gliomas are below the level of
measurement of MRS making 2HG a specific marker for IDH1+ mutated gliomas. Approach: We will create a
standardized MRS protocol that accounts for initial variations in tumor presentation during the vaccine
application period, prior to tumor resection. We have partnered with a consortium for clinical translation of MRS
methods at Massachusetts General Hospital (MGH) headed by Dr. Ovidiu Andronesi. We will create a
standard protocol for 2HG measures using 1) the MGH 2HG proven MEGA-LASER pulse sequence for
Siemens MR scanners; 2) Siemens’ automatic voxel alignment software for longitudinal voxel re-positioning;
and, 3) Dr. Soher’s open source “Vespa” software for spectral simulation and fitting of the MEGA-LASER data.
We will demonstrate feasibility and repeatability of the method in a multiple time point workflow, and measure
same-day metabolite coefficients of variance in order to power its use in Phase II trials. We will measure 2HG
in all patients receiving the IDH1+ vaccine. Patients will be scanned on our research Siemens Trio scanner at
five time points across approximately 6-8 weeks they receive vaccine prior to surgical resection. Impact: Our
long-term hypothesis is that an MRS protocol optimized for 2HG can provide clinicians with robust metabolic
measures which provide direct, and possibly earlier, measures of the effects of therapeutic interventions than
other MR measures such as tumor enhancement with/without contrast. The current proposal provides an
unparalleled opportunity to work collaboratively with our parent Phase I immunotherapy treatment trial to
optimize a well characterized tool for quantitation of tumor metabolism for use in subsequent Phase II trials.
We will determine best practices for taking 2HG measures in this patient set and demonstrate the feasibility of
including this measure into our research/clinical workflow in terms of patient tolerance and data robustness.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MrSPA: Integrated tools and development platform for magnetic resonance research
-
批准号:7557960
-
项目类别:
-
资助金额:$41.52万
-
财政年份:2008
-
负责人:Brian J Soher
-
依托单位:
MrSPA: Integrated tools and development platform for magnetic resonance research
-
批准号:7686273
-
项目类别:
-
资助金额:$40.81万
-
财政年份:2008
-
负责人:Brian J Soher
-
依托单位:
MrSPA: Integrated tools and development platform for magnetic resonance research
-
批准号:7907700
-
项目类别:
-
资助金额:$41.98万
-
财政年份:2008
-
负责人:Brian J Soher
-
依托单位:
MOTION CORRECTED MR SPECTROSCOPIC IMAGING IN HUMANS
-
批准号:2685633
-
项目类别:
-
资助金额:$3.02万
-
财政年份:1998
-
负责人:Brian J Soher
-
依托单位:
MOTION CORRECTED MR SPECTROSCOPIC IMAGING IN HUMANS
-
批准号:2036961
-
项目类别:
-
资助金额:$2.54万
-
财政年份:1997
-
负责人:Brian J Soher
-
依托单位:
海外基金